FCR achieves long-term durable remissions in patients with IGHV-mutated CLL-Reference-Cited by-同舟云学术

FCR achieves long-term durable remissions in patients with IGHV-mutated CLL

Published:2017-11-23 Issue:21 Volume:130 Page:2278-2282
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Chai-Adisaksopha Chatree¹²,Brown Jennifer R.³

Affiliation:

1. Department of Medicine and

2. Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada; and

3. CLL Center, Division of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA

Abstract

Abstract In chronic lymphocytic leukemia (CLL) patients with mutated IGHV, 3 recent studies have demonstrated prolonged progression-free survival (PFS) after treatment with fludarabine-cyclophosphamide-rituximab (FCR) chemoimmunotherapy. We performed a systematic review to assess the benefit of FCR for patients with CLL and identified 5 randomized trials that met our inclusion criteria. FCR improved complete remission, PFS and overall survival vs the comparator; median PFS was not reached in the subgroup of CLL patients with mutated IGHV.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/130/21/2278/1403323/blood731588.pdf

Reference34 articles.

1. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia;Rai;N Engl J Med,2000

2. Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia;Eichhorst;Blood,2006

3. Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997;Flinn;J Clin Oncol,2007

4. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia;Keating;J Clin Oncol,2005

5. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial;Hallek;Lancet,2010

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cost-Effectiveness Analysis of Rituximab for Chronic Lymphocytic Leukemia Using a Semi-Markovian Model Approach in R;Value in Health Regional Issues;2023-07

2. Integrin Signaling Shaping BTK-Inhibitor Resistance;Cells;2022-07-18

3. A Ferroptosis Molecular Subtype-Related Signature for Predicting Prognosis and Response to Chemotherapy in Patients with Chronic Lymphocytic Leukemia;BioMed Research International;2022-07-06

4. Diagnosis, treatment and supportive management of chronic lymphocytic leukemia: recommendations of the Dutch HOVON CLL working group;Leukemia & Lymphoma;2022-06-23

5. Secondary primary malignancies after treatment with chemo-immunotherapy in treatment-naïve patients with CLL: a systematic literature review;Expert Review of Hematology;2022-02-24